Intellia Therapeutics Terminates Deal with Regeneron
Ticker: NTLA · Form: 8-K · Filed: Mar 22, 2024 · CIK: 1652130
Sentiment: neutral
Topics: termination, collaboration, gene-editing
Related Tickers: REGN
TL;DR
Intellia just axed its big deal with Regeneron, major partnership shakeup.
AI Summary
Intellia Therapeutics, Inc. announced on March 19, 2024, the termination of its material definitive agreement with Regeneron Pharmaceuticals, Inc. This termination is related to their collaboration on CRISPR-based gene editing therapies. The company did not disclose specific financial implications of this termination in the filing.
Why It Matters
The termination of this material agreement could impact Intellia's development pipeline and strategic partnerships, potentially affecting future revenue streams and research progress.
Risk Assessment
Risk Level: medium — The termination of a material definitive agreement, especially one involving a significant partner like Regeneron, introduces uncertainty regarding Intellia's strategic direction and future development capabilities.
Key Players & Entities
- Intellia Therapeutics, Inc. (company) — Registrant
- Regeneron Pharmaceuticals, Inc. (company) — Partner in terminated agreement
- March 19, 2024 (date) — Date of earliest event reported
- CRISPR (technology) — Technology used in collaboration
FAQ
What was the specific material definitive agreement that was terminated?
The filing states that a material definitive agreement was terminated, but does not specify its exact title or terms beyond its relation to CRISPR-based gene editing therapies.
When was the termination effective?
The date of the earliest event reported is March 19, 2024, which is when the termination is indicated to have occurred.
What is the impact of this termination on Intellia's ongoing research and development?
The filing does not detail the specific impact on ongoing research and development, but the termination of a material agreement with a partner like Regeneron suggests a significant shift in strategy or collaboration.
Are there any financial penalties or obligations associated with this termination?
The filing does not disclose any specific financial penalties or obligations resulting from the termination of the agreement.
Did Intellia Therapeutics, Inc. provide a reason for the termination?
The filing does not provide a specific reason for the termination of the material definitive agreement.
Filing Stats: 1,031 words · 4 min read · ~3 pages · Grade level 16.2 · Accepted 2024-03-22 09:26:31
Key Financial Figures
- $0.0001 — ich registered Common Stock (Par Value $0.0001) NTLA The Nasdaq Global Market Ind
- $320.0 million — tellia may be eligible to receive up to $320.0 million in milestone payments and royalties in
Filing Documents
- d17601d8k.htm (8-K) — 28KB
- 0001193125-24-074706.txt ( ) — 148KB
- ntla-20240319.xsd (EX-101.SCH) — 3KB
- ntla-20240319_lab.xml (EX-101.LAB) — 18KB
- ntla-20240319_pre.xml (EX-101.PRE) — 11KB
- d17601d8k_htm.xml (XML) — 4KB
Forward Looking Statements
Forward Looking Statements. This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. The words "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, but are not limited to, express or implied statements regarding the Company's beliefs and expectations regarding: the termination of the Co-Co Agreement and the development of gene editing products directed to factor IX under the LCA, including the Company's obligations under the LCA, Regeneron's continued development of such products, and potential milestone payments and royalties related to such products. Any forward-looking statements in this Current Report on Form 8-K are based on management's current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: risks related to the Company's ability to protect and maintain its intellectual property position; risks related to the Company's relationship with third parties, including Regeneron; and risks related to the Company's or its collaborators' ability to develop and commercialize product candidates successfully, including gene editing products directed to factor IX. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in the Company's
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Intellia Therapeutics, Inc. Date: March 22, 2024 By: /s/ John M. Leonard Name: John M. Leonard Title: Chief Executive Officer and President